e-learning
resources
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Reflux in idiopathic pulmonary fibrosis: treatment informed by an integrated approach
Rhys Jones, Amaran Krishnan, Gemma L. Zeybel, Emily Dookun, Jeffrey P. Pearson, A. John Simpson, S. Michael Griffin, Chris Ward, Ian A. Forrest
Source:
ERJ Open Res, 4 (4) 00051-2018; 10.1183/23120541.00051-2018
Journal Issue:
October
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Rhys Jones, Amaran Krishnan, Gemma L. Zeybel, Emily Dookun, Jeffrey P. Pearson, A. John Simpson, S. Michael Griffin, Chris Ward, Ian A. Forrest. Reflux in idiopathic pulmonary fibrosis: treatment informed by an integrated approach. ERJ Open Res, 4 (4) 00051-2018; 10.1183/23120541.00051-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Emerging classes of drugs for the treatment of obstructive lung disease
Related content which might interest you:
Nutritional assessment in patients with idiopathic pulmonary fibrosis: the NUTRIPF study
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Diagnosis of idiopathic pulmonary fibrosis: from guidelines to clinical practice
Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease
Year: 2009
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF
Source: Eur Respir J 2015; 46: 883-886
Year: 2015
Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines
Source: Eur Respir Rev 2014; 23:193-214
Year: 2014
The lived experience of idiopatic pulmonary fibrosis: A qualitative study
Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences
Year: 2016
Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Follow-up and nonpharmacological management of the idiopathic pulmonary fibrosis patient
Source: Eur Respir Rev 2011; 20: 114-117
Year: 2011
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
Source: Eur Respir J 2015; 46: 186-196
Year: 2015
The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches
Source: Eur Respir J 2006; 28: 463-465
Year: 2006
Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient
Source: Eur Respir J 2016; 47: 1057-1059
Year: 2016
Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation
Source: Eur Respir J 2012; 40: 794-795
Year: 2012
Idiopathic pulmonary fibrosis: present understanding and future options
Source: Eur Respir Rev 2011; 20: 132-133
Year: 2011
A supportive care decision aid tool for idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept